Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Mitoxantrone Hydrochloride Liposome
The First People's Hospital of Lianyungang
Acute Myeloid Leukemia (AML)
1 trial -
Dexamethason 4 mg JENAPHARM®, Dexamethasone Tablets BP 2.0mg, CRISANTASPASE, Dexamethason 0,5 mg JENAPHARM®, Vincristine Sulfate 1 mg/ml solution for injection, Oncaspar 750 U/ml powder for solution for injection/infusion., Dexamethasone 3.3 mg/mL Solution for injection, MITOXANTRONE HYDROCHLORIDE, BESPONSA 1 mg powder for concentrate for solution for infusion
Pfizer Australia Pty Ltd
Acute Lymphoblastic Leukemia (ALL)
1 trial -
Mitoxantrone Hydrochloride Liposome
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Diffuse Large B-cell Lymphoma
1 trial -
Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride and Dexamethasone (P-GEMD) regimen
The First People's Hospital of Lianyungang
NK-T-Cell Lymphoma, Extranodal
1 trial -
mitoxantrone hydrochloride liposome
The First People's Hospital of Lianyungang
Relapsed/Refractory Acute Myeloid Leukaemia
2 trials -
Liposomal Mitoxantrone Hydrochloride dose level 1
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Non Hodgkin Lymphoma
1 trial -
mitoxantrone hydrochloride
Karyopharm Therapeutics Inc
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
1 trial -
Mitoxantrone hydrochloride liposome injection
The First People's Hospital of Lianyungang
Diffuse Large B-cell Lymphoma
1 trial -
Mitoxantrone hydrochloride liposome injection30mg/m2
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Acute Myeloid Leukemia
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources